

Please type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/520,474
				Filing Date	05/30/2003
				First Named Inventor	Thomas Hunig
				Group Art Unit	Unassigned
				Confirmation No.	6842
				Examiner Name	Unassigned
Sheet		1	of	1	Attorney Docket Number
					7003/31

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Issue Date MM-DD-YYYY
		Number	Class/Subclass		

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Applications		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Class/Subclass		
1	2002/0058019 A1	424/93.7	Berenson et al.	05-16-2002	

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office <sup>3</sup>	Number	Class/Subclass			
1	DE	100 50 935 A1	A61K 39/395	Tegenero GmbH	05-02-2002		

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>2</sup>
	1	Bonhyadi, M. et al., "XCELLERATE: AN AUTOLOGOUS T CELL IMMUNOTHERAPY APPROACH FOR TREATING B- CELL LYMPHOCYTIC LEUKEMIA (B-CLL)," <i>Blood</i> , Nov. 16, 2000, Abstract only, 1 page.					
	2	Broeren, Chris P. et al., "Costimulation Light: Activation of CD4+ T Cells with CD80 or CD86 Rather Than Anti-DC28 Leads to a TH2 Cytokine Profile," <i>The Journal of Immunology</i> , 2000, 165: 6908-6914.					
	3	Mengozzi, Manuela et al., "Naïve CD4 cells inhibit CD28-costimulated R5 HIV replication in memory CD4 T cells," <i>PNAS</i> , September 25, 2001, vol. 98, no. 20, pp. 11644-11649.					
	4	Dynabeads® M-450 Tosylactivated, Dynal® Biotech, pp. 1-8, date unknown, but prior to the filing date of the instant application.(07/04/2002) .					
	5	"Are you new to the Dynabeads® Technology?," <a href="http://www.dynal.no/kunder/dynal/dynalpub401.nsf/print/9F9F14DDD7BF78E6C125...">http://www.dynal.no/kunder/dynal/dynalpub401.nsf/print/9F9F14DDD7BF78E6C125...</a> , downloaded 07/21/2003, 2 pages.					

Examiner Signature	/Ilia Ouspenski/	Date Considered	08/24/2010
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.